Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verve Therapeutics (VERV)
NASDAQ:VERV
Verve Therapeutics (VERV) Stock Price & Analysis
419 Followers
VERV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.84 - $21.42
Previous Close$5.98
Volume2.19M
Average Volume (3M)1.38M
Market Cap
$469.72M
Enterprise Value-$79.32M
Total Cash (Recent Filing)$623.95M
Total Debt (Recent Filing)$74.91M
Price to Earnings (P/E)-2.1
Beta2.62
Next Earnings
Aug 08, 2024EPS Estimate
-$0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding83,965,493
10 Day Avg. Volume1,552,429
30 Day Avg. Volume1,380,680
Standard Deviation0.27
R-Squared0.14
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.84
Price to Sales (P/S)97.61
Price to Cash Flow (P/CF)-3.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-15.42
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.50
Forecast
1Y Price Target
$28.00Price Target Upside368.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Verve Therapeutics News
PremiumCompany Announcements
Verve Therapeutics’ Financial Outlook Threatened by CRISPR Patent Disputes
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressFirst patient dosed in VERVE-102 Heart-2 trial; data expected in 2025.
Financial StabilityVerve's strong cash position is expected to fund operations and major pipeline developments through late 2026.
Therapeutic PotentialVERVE-101 shows promising proof-of-concept with significant LDL-C reductions, demonstrating potential effectiveness in treating hypercholesterolemia.
Bears Say
Clinical Trial ConcernsA sixth patient experienced transient increase in serum ALT and drug-induced thrombocytopenia, which led to a pause in the Phase 1b trial of VERVE-101.
Financial HealthVerve reported a net loss of $48.7M for Q1 2024, with an increased R&D spend and G&A expenses compared to the previous year.
Safety Profile IssuesSafety concerns arise with transient elevations in ALT and one patient experiencing a myocardial infarction potentially related to VERVE-101.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VERV FAQ
What was Verve Therapeutics’s price range in the past 12 months?
Verve Therapeutics lowest stock price was $5.84 and its highest was $21.42 in the past 12 months.
What is Verve Therapeutics’s market cap?
Currently, no data Available
When is Verve Therapeutics’s upcoming earnings report date?
Verve Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 80 days.
How were Verve Therapeutics’s earnings last quarter?
Verve Therapeutics released its earnings results on May 08, 2024. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.702 by $0.112.
Is Verve Therapeutics overvalued?
According to Wall Street analysts Verve Therapeutics’s price is currently Undervalued.
Does Verve Therapeutics pay dividends?
Verve Therapeutics does not currently pay dividends.
What is Verve Therapeutics’s EPS estimate?
Verve Therapeutics’s EPS estimate is -$0.66.
How many shares outstanding does Verve Therapeutics have?
Verve Therapeutics has 78,549,065 shares outstanding.
What happened to Verve Therapeutics’s price movement after its last earnings report?
Verve Therapeutics reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.702. Following the earnings report the stock price went down -1.299%.
Which hedge fund is a major shareholder of Verve Therapeutics?
Among the largest hedge funds holding Verve Therapeutics’s share is ARK Investment Management LLC. It holds Verve Therapeutics’s shares valued at 98M.
---
Verve Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.00 (368.23% Upside)
$28.00 (368.23% Upside)
Blogger Sentiment
Bullish
VERV Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $475.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.11%
12-Months-Change
Fundamentals
Return on Equity
-36.03%
Trailing 12-Months
Asset Growth
15.45%
Trailing 12-Months
Company Description
Verve Therapeutics
Verve Therapeutics Inc is a genetic medicines company pioneering the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Its initial programs focus on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. The company is developing these gene-editing treatments for patients with familial hypercholesterolemia, a genetic disease that causes life-long severely elevated blood cholesterol.
---
VERV Stock 12 Month Forecast
Average Price Target
$28.00
▲(368.23% Upside)
Technical Analysis
Best Analysts Covering VERV
1 Year
1 Year Success Rate
1/12 ratings generated profit
1 Year Average Return
-38.82%
reiterated a buy rating 2 months ago
Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 8.33% of your transactions generating a profit, with an average return of -38.82% per trade.
---